NABTT0502：厄洛替尼和索拉非尼治疗进展或复发性多形性胶质母细胞瘤患者的 II 期和药代动力学研究。
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
机构信息
Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.
出版信息
Neuro Oncol. 2013 Apr;15(4):490-6. doi: 10.1093/neuonc/nos322. Epub 2013 Jan 17.
Abstract
BACKGROUND
The signal transduction pathways of epidermal growth factor receptor and Ras are both important in the growth of glioblastoma multiforme (GBM). We hypothesized that inhibition of both pathways would improve the survival time of patients with recurrent GBM.
METHODS
Patients with recurrent/progressive GBM with 0-2 prior chemotherapy regimens received erlotinib 150 mg once daily and sorafenib 400 mg twice daily until progression. The primary endpoint was overall survival. Pharmacokinetic sampling was performed during cycle 1.
RESULTS
The median overall survival was 5.7 months. Progression-free survival at 6 months was 14%. Toxicity was manageable. Clearance of erlotinib was markedly enhanced by sorafenib.
CONCLUSION
The study did not meet its objective of a 30% increase in overall survival time compared with historical controls. Erlotinib and sorafenib have significant pharmacokinetic interactions that may negatively impact the efficacy of the combination regimen.
摘要
背景
表皮生长因子受体和 Ras 的信号转导通路在多形性胶质母细胞瘤（GBM）的生长中都很重要。我们假设抑制这两条通路将改善复发性 GBM 患者的生存时间。
方法
接受过 0-2 种化疗方案的复发性/进行性 GBM 患者每日接受厄洛替尼 150mg 和索拉非尼 400mg 治疗，每日两次，直到疾病进展。主要终点是总生存期。在第 1 周期进行药代动力学采样。
结果
中位总生存期为 5.7 个月。6 个月时无进展生存率为 14%。毒性可控制。索拉非尼显著增强厄洛替尼的清除率。
结论
该研究未达到与历史对照相比总生存时间增加 30%的目标。厄洛替尼和索拉非尼具有显著的药代动力学相互作用，可能会降低联合治疗方案的疗效。
相似文献
1
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.NABTT0502：厄洛替尼和索拉非尼治疗进展或复发性多形性胶质母细胞瘤患者的 II 期和药代动力学研究。
Neuro Oncol. 2013 Apr;15(4):490-6. doi: 10.1093/neuonc/nos322. Epub 2013 Jan 17.
2
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.索拉非尼联合替西罗莫司治疗复发性胶质母细胞瘤或胶质肉瘤的 I/II 期研究：北美脑肿瘤联盟研究 05-02。
Neuro Oncol. 2012 Dec;14(12):1511-8. doi: 10.1093/neuonc/nos264. Epub 2012 Oct 24.
3
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.厄洛替尼和替西罗莫司治疗复发性恶性脑胶质瘤患者的 I/II 期研究：北美脑肿瘤联盟试验 04-02。
Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.
4
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.CYP3A 诱导型抗癫痫药物对索拉非尼暴露的影响：索拉非尼联合替莫唑胺每日治疗复发性胶质母细胞瘤成人患者的 II 期研究结果。
J Neurooncol. 2011 Jan;101(1):57-66. doi: 10.1007/s11060-010-0217-6. Epub 2010 May 5.
5
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.贝伐珠单抗联合索拉非尼治疗复发性胶质母细胞瘤的 II 期研究（N0776）：一项中北部癌症治疗组试验。
Clin Cancer Res. 2013 Sep 1;19(17):4816-23. doi: 10.1158/1078-0432.CCR-13-0708. Epub 2013 Jul 5.
6
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.贝伐珠单抗联合厄洛替尼治疗复发性恶性脑胶质瘤的Ⅱ期临床试验
Neuro Oncol. 2010 Dec;12(12):1300-10. doi: 10.1093/neuonc/noq099. Epub 2010 Aug 17.
7
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.索拉非尼与厄洛替尼用于晚期胰腺癌的II期试验。
Cancer Med. 2014 Jun;3(3):572-9. doi: 10.1002/cam4.208. Epub 2014 Feb 12.
8
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).索拉非尼联合厄洛替尼治疗晚期非小细胞肺癌的多中心II期研究（KCSG-0806）
Lung Cancer. 2016 Mar;93:1-8. doi: 10.1016/j.lungcan.2015.12.005. Epub 2015 Dec 29.
9
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.一项厄洛替尼治疗复发性恶性胶质瘤和放疗后非进展性多形性胶质母细胞瘤患者的 II 期临床试验。
Neuro Oncol. 2010 Jan;12(1):95-103. doi: 10.1093/neuonc/nop015. Epub 2009 Dec 14.
10
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.一项厄洛替尼和索拉非尼在化疗初治的晚期非小细胞肺癌患者中的多中心 II 期研究。
Clin Cancer Res. 2010 Jun 1;16(11):3078-87. doi: 10.1158/1078-0432.CCR-09-3033. Epub 2010 Apr 15.
引用本文的文献
1
Targeting Glioma Stem Cells: Therapeutic Opportunities and Challenges.靶向胶质瘤干细胞：治疗机遇与挑战
Cells. 2025 May 6;14(9):675. doi: 10.3390/cells14090675.
2
Kinase-Targeted Therapies for Glioblastoma.胶质母细胞瘤的激酶靶向治疗
Int J Mol Sci. 2025 Apr 15;26(8):3737. doi: 10.3390/ijms26083737.
3
A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy.美国食品药品监督管理局（FDA）批准的用于脑肿瘤治疗的多靶点血管生成药物综述。
Int J Mol Sci. 2025 Feb 28;26(5):2192. doi: 10.3390/ijms26052192.
4
Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration.胶质母细胞瘤靶向治疗的挑战与进展：药物重新利用和生物标志物探索的前景
Front Oncol. 2024 Oct 8;14:1441460. doi: 10.3389/fonc.2024.1441460. eCollection 2024.
5
Understanding the Role of Endothelial Cells in Glioblastoma: Mechanisms and Novel Treatments.了解内皮细胞在胶质母细胞瘤中的作用：机制与新疗法。
Int J Mol Sci. 2024 Jun 1;25(11):6118. doi: 10.3390/ijms25116118.
6
Glioblastoma Therapy: Past, Present and Future.胶质母细胞瘤治疗：过去、现在和未来。
Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529.
7
Personalized Medicine in Brain Gliomas: Targeted Therapy, Patient-Derived Tumor Models (Review).脑胶质瘤的个性化医疗：靶向治疗、患者来源的肿瘤模型（综述）
Sovrem Tekhnologii Med. 2023;15(3):61-71. doi: 10.17691/stm2023.15.3.07. Epub 2023 May 28.
8
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.表皮生长因子受体抑制剂在脑胶质瘤中的应用：现状与未来可能。
Int J Mol Sci. 2024 Feb 15;25(4):2316. doi: 10.3390/ijms25042316.
9
Targeted Glioma Therapy-Clinical Trials and Future Directions.靶向胶质瘤治疗——临床试验与未来方向
Pharmaceutics. 2024 Jan 11;16(1):100. doi: 10.3390/pharmaceutics16010100.
10
From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.从信号通路到靶向治疗：揭示胶质母细胞瘤的秘密并利用二十年来的进展。
Signal Transduct Target Ther. 2023 Oct 20;8(1):400. doi: 10.1038/s41392-023-01637-8.
本文引用的文献
1
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.索拉非尼治疗复发性或进行性恶性脑胶质瘤患者的 I 期临床试验。
Neuro Oncol. 2011 Dec;13(12):1324-30. doi: 10.1093/neuonc/nor145. Epub 2011 Sep 27.
2
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.酪氨酸激酶抑制剂的临床药代动力学：以 4-苯胺基喹唑啉类为重点。
Clin Pharmacokinet. 2011 Jun;50(6):371-403. doi: 10.2165/11587020-000000000-00000.
3
Erlotinib and pantoprazole: a relevant interaction or not?厄洛替尼和泮托拉唑：存在相关相互作用？还是没有？
Br J Clin Pharmacol. 2010 Dec;70(6):908-11. doi: 10.1111/j.1365-2125.2010.03748.x.
4
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.乳腺癌耐药蛋白（ABCG2）在索拉非尼向脑部分布中的作用。
J Pharmacol Exp Ther. 2011 Jan;336(1):223-33. doi: 10.1124/jpet.110.175034. Epub 2010 Oct 15.
5
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.贝伐珠单抗联合厄洛替尼治疗复发性恶性脑胶质瘤的Ⅱ期临床试验
Neuro Oncol. 2010 Dec;12(12):1300-10. doi: 10.1093/neuonc/noq099. Epub 2010 Aug 17.
6
Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report.厄洛替尼治疗 von Hippel-Lindau 病相关中枢神经系统血管母细胞瘤病：病例报告。
J Neurooncol. 2011 Jan;101(2):307-10. doi: 10.1007/s11060-010-0244-3. Epub 2010 Jun 4.
7
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.一项厄洛替尼和索拉非尼在化疗初治的晚期非小细胞肺癌患者中的多中心 II 期研究。
Clin Cancer Res. 2010 Jun 1;16(11):3078-87. doi: 10.1158/1078-0432.CCR-09-3033. Epub 2010 Apr 15.
8
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.高级别胶质瘤更新后的反应评估标准：神经肿瘤学工作组的反应评估。
J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.
9
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.一项厄洛替尼治疗复发性恶性胶质瘤和放疗后非进展性多形性胶质母细胞瘤患者的 II 期临床试验。
Neuro Oncol. 2010 Jan;12(1):95-103. doi: 10.1093/neuonc/nop015. Epub 2009 Dec 14.
10
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.一项在非进展性胶质母细胞瘤多形性放疗后、复发性恶性神经胶质瘤和脑膜瘤患者中进行厄洛替尼的 I 期临床试验。
Neuro Oncol. 2010 Jan;12(1):87-94. doi: 10.1093/neuonc/nop017. Epub 2009 Dec 14.
Zotero 插件